Migraine is painful headaches which are basic for an irregularly incapacitating neurovascular disorder that distresses younger adults, especially women due to regular changes in hormones. They can be preceded or accompanied by sensory warning signs and additional symptoms. The therapeutics can be either preventive or failed, caters to the treatment of acute or chronic migraine where the headache frequency and severity can be successfully controlled.
The Global Migraine Drugs Market was valued at $3.9Bn in 2018 and is forecasted to grow at a strong 9.73% CAGR between 2018 and 2026, resulting in 2026 global sales of $8.2Bn. The market-driven growing uptake of novel drug classes and the rising prevalence of migraines are some of the components boosting the market. However, lack of proper diagnosis and undiagnosed cases and side effects with migraine drugs are some of the components restricting the growth of the market. Moreover, the improvement of an inaccurate diagnosis of the condition will provide ample opportunities to the market.
Migraine Drugs Market depending on therapeutic classes, triptans segment is dominated due to it demonstrate variable selectivity for the 5-HT1F receptor that is expressed in neurons and not for blood vessels and until recently it was largely overshadowed in terms of potential migraine therapies. These triptans more effective in relieving the pain and other symptoms that are associated with migraines and they evaluated the oral tablet, nasal spray, and subcutaneous injection versus placebo or other treatments.
The Global Migraine Drugs Market is segmented on the basis of Treatment, Route of Administration, Therapeutic Class, Distribution Channel, and Region.
Based on the Treatment: Preventative and Abortive
Based on the Route of Administration: Oral, Injectables, and Others
Based on the Therapeutic class: Nonsteroidal anti-inflammatory drug (NSAIDs), Alkaloids, Ergot and Triptans.
Based on the Distribution Channel: Hospital-based Pharmacies, Retail Pharmacies, and Online Pharmacies.
Based on Region: North America, Asia-Pacific, Europe, and LAMEA. Among that Asia pacific is projected to witness high growth during the forecasted period due to developing several headache cases and growing public awareness about the disease. For the most part, India and China are significant market has there is a high existences headache in these countries. Moreover, migraine continues to be an undertreated disease and underdiagnosed in India, resulting from myths and misconceptions surrounding the illness including incorrect diagnosis and triggers in the Indian migraine patients are similar to other populations but for dietary factors.
The key players of the Global Migraine Drugs Market include Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Novartis International AG, Allergan plc, Impel NeuroPharma Inc. and etc..
Report Description: The report covers in-depth analysis of the Global Migraine Drugs Market. The report assesses the market products pipeline by Route of Administration (Injectables, Oral) by Therapeutic Class (Triptans, Ergot, NSAID's, CGRP antagonists and antibodies), by Treatment Class (Abortive, Prophylactic) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Migraine Drugs Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.